Toripalimab is a novel humanized immunoglobin G4 monoclonal antibody against PD-1.17 Several phase 1/2 clinical trials of toripalimab have exhibited its manageable safety profile and promising antitumor activity among patients with advanced melanoma, urothelial cancer, renal cell cancer, and advanced gastric cancer.18,19 However, the performance of toripalimab in patients with NSCLC has not been established. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.